ARCHIVES

As FDA Weighs its Options on Morcellation, Debate Erupts Over Harvard Device Study

This article is from The Cancer Letter archive.

Vol. 40 No. 44 | November 21, 2014

Download PDF Visit The Full Archive

Related Articles

ASCO: NCI Director Should Be A Clinician; NBCC Endorses Mary-Claire King

March 10, 1995

White House appoints NCI Director Andrew von Eschenbach acting FDA commissioner after Lester Crawford resigns.

September 30, 2005

Berlin, DeVita Differ On Use Of L-PAM

November 8, 1974

In Brief: House, Senate Differ On NCI Positions; Upton Says Viral Oncology research Will Be Continued

August 12, 1977

DeVita Era At NCI One Of New Programs, Remarkable Stability

August 19, 1988

New CCOP RFA To Encourage Cancer Control Research; Larger But Fewer Awards Are Likely

May 9, 1986